Dataset Information

Curation of an international drug proprietary names dataset

ABSTRACT: A drug dataset containing international proprietary names is essential for researchers investigating different drugs from different countries worldwide. However, many websites on the internet offer free access for a single drug searching service to identify international drug trade names, but not for a list of drugs to be searched and identified. Therefore, it will be problematic if the researcher has a list of hundreds or thousands of drug trade names to be identified. In this project, we have created an International Drug Dictionary (IDD) by curating collected drug lists from open access websites belonging to official drug regulatory agencies, official healthcare systems, or recognized scientific bodies from 44 countries around the world in addition to the European public assessment reports (EPAR) and the DRUGBANK vocabulary published in the public domain. Researchers interested in pharmacovigilance, pharmacoepidemiology, or pharmacoeconomics can benefit from this dataset, especially when identifying lists of proprietary drug names, particularly of multi-national origin. To enhance its adaptability, we also mapped the IDD to the standardized drug vocabulary RxNorm. The IDD can also be used as a tool for mapping international drug trade names to RxNorm. Each drug entity in the IDD mapped to a unique identification number for each entity called Atom Unique Identifier (RXAUI) from RxNorm.

SUBMITTER: Khaleel M

PROVIDER: S-EPMC8703051 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundCamellias are popular ornamental, tea and woody-oil plants that have been cultivated throughout the world for centuries. To date, over 23,000 cultivars, with more than 45,000 cultivar names including synonyms, have been registered or published. A global digital dataset of Camellia names will provide a validated reference which can then serve to prevent further duplication when selecting names for new cultivars and assist in clearing up some of the confusion that still clings to a few of the old cultivar names. This comprehensive compendium is our review of camellia cultivars through history.New informationThe camellia cultivar names were collected from books and journals, as well as new registrations. These were then reviewed by experts in the online working platform, the Database of International Camellia Register (DICR). After treating and correcting important issues that existed in camellia names, especially those with many re-used names and diacritical marks etc. in Japanese cultivars, a dataset of camellia names from sources throughout the world was summarised from the year 1253 to 2019. To date, a total of 45,210 cultivar names were released by different countries, including 23,887 accepted names and 21,323 synonyms. Excluding 3,944 names believed extinct, a total of 19,944 cultivar names are still in use. Amongst camellia cultivars, most (23,449) were for ornamental use, 429 were additionally used for tea and 228 for oil. Camellia japonica and its hybrids represent 18,141 or 74.10%, followed by those of C. reticulata and its hybrids (1,432 or 5.85%) and C. sasanqua and its hybrids (1,291 or 5.27%). The top five countries of origin are USA (7,502 cultivars), Japan (6,592), Italy (2,833), China (2,066) and Australia (1,216). The data showed the number of camellia cultivars per country is somewhat related to each country's economic prosperity. Managed by the International Camellia Registration team, this is the most comprehensive dataset in the genus Camellia. It will facilitate quick reference and scientific naming for breeders.

Project description:BackgroundConfusion between look-alike and sound-alike (LASA) medication names (such as mercaptamine and mercaptopurine) accounts for up to one in four medication errors, threatening patient safety. Error reduction strategies include computerized physician order entry interventions, and 'Tall Man' lettering. The purpose of this study is to explore the medication name designation process, to elucidate properties that may prime the risk of confusion.Methods and findingsWe analysed the formal and semantic properties of 7,987 International Non-proprietary Names (INNs), in relation to naming guidelines of the World Health Organization (WHO) INN programme, and have identified potential for errors. We explored: their linguistic properties, the underlying taxonomy of stems to indicate pharmacological interrelationships, and similarities between INNs. We used Microsoft Excel for analysis, including calculation of Levenshtein edit distance (LED). Compliance with WHO naming guidelines was inconsistent. Since the 1970s there has been a trend towards compliance in formal properties, such as word length, but longer names published in the 1950s and 1960s are still in use. The stems used to show pharmacological interrelationships are not spelled consistently and the guidelines do not impose an unequivocal order on them, making the meanings of INNs difficult to understand. Pairs of INNs sharing a stem (appropriately or not) often have high levels of similarity (<5 LED), and thus have greater potential for confusion.ConclusionsWe have revealed a tension between WHO guidelines stipulating use of stems to denote meaning, and the aim of reducing similarities in nomenclature. To mitigate this tension and reduce the risk of confusion, the stem system should be made clear and well ordered, so as to avoid compounding the risk of confusion at the clinical level. The interplay between the different WHO INN naming principles should be further examined, to better understand their implications for the problem of LASA errors.

Dataset Information

Curation of an international drug proprietary names dataset

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets